Akero Therapeutics, Inc. (NASDAQ:AKRO) Director G. Walmsley Graham Purchases 91,309 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) Director G. Walmsley Graham purchased 91,309 shares of the stock in a transaction dated Tuesday, March 25th. The shares were acquired at an average cost of $44.75 per share, with a total value of $4,086,077.75. Following the acquisition, the director now directly owns 1,091,309 shares in the company, valued at $48,836,077.75. This represents a 9.13 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

G. Walmsley Graham also recently made the following trade(s):

• On Thursday, March 27th, G. Walmsley Graham bought 50,000 shares of Akero Therapeutics stock. The stock was acquired at an average price of $43.55 per share, for a total transaction of $2,177,500.00.
• On Thursday, January 30th, G. Walmsley Graham bought 200,000 shares of Akero Therapeutics stock. The stock was bought at an average cost of $48.00 per share, with a total value of $9,600,000.00.

Akero Therapeutics Trading Up 0.7 %

AKRO traded up $0.29 during midday trading on Thursday, hitting $43.58. 441,531 shares of the company were exchanged, compared to its average volume of 805,011. The firm’s 50 day moving average price is $45.66 and its 200-day moving average price is $34.90. Akero Therapeutics, Inc. has a 1-year low of $17.86 and a 1-year high of $58.40. The firm has a market capitalization of $3.47 billion, a P/E ratio of -11.62 and a beta of -0.19. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01). As a group, equities analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AKRO. abrdn plc raised its stake in Akero Therapeutics by 118.7% during the fourth quarter. abrdn plc now owns 269,782 shares of the company’s stock worth $7,505,000 after buying an additional 146,424 shares during the last quarter. FMR LLC raised its position in shares of Akero Therapeutics by 732.1% in the 3rd quarter. FMR LLC now owns 30,337 shares of the company’s stock worth $870,000 after acquiring an additional 26,691 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Akero Therapeutics by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company’s stock valued at $15,042,000 after purchasing an additional 8,096 shares during the period. Proficio Capital Partners LLC acquired a new position in shares of Akero Therapeutics in the 4th quarter valued at about $320,000. Finally, SG Americas Securities LLC boosted its position in shares of Akero Therapeutics by 4,022.1% during the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock valued at $16,636,000 after purchasing an additional 583,486 shares in the last quarter.

Analyst Ratings Changes

AKRO has been the subject of a number of research analyst reports. Morgan Stanley reiterated an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Bank of America upgraded Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. UBS Group boosted their price objective on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Citigroup increased their target price on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Finally, HC Wainwright boosted their price target on Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $76.29.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.